[HTML][HTML] Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin
Antibodies have created high expectations for effective yet tolerated therapeutics in acute
myeloid leukemia (AML). Hitherto the most exploited target is CD33, a myeloid differentiation …
myeloid leukemia (AML). Hitherto the most exploited target is CD33, a myeloid differentiation …
Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin
AJ Cowan, GS Laszlo, EH Estey… - Frontiers in …, 2013 - pubmed.ncbi.nlm.nih.gov
Antibodies have created high expectations for effective yet tolerated therapeutics in acute
myeloid leukemia (AML). Hitherto the most exploited target is CD33, a myeloid differentiation …
myeloid leukemia (AML). Hitherto the most exploited target is CD33, a myeloid differentiation …
Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin
AJ Cowan, GS Laszlo, EH Estey… - Frontiers in Bioscience …, 2013 - imrpress.com
Antibodies have created high expectations for effective yet tolerated therapeutics in acute
myeloid leukemia (AML). Hitherto the most exploited target is CD33, a myeloid differentiation …
myeloid leukemia (AML). Hitherto the most exploited target is CD33, a myeloid differentiation …
Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin.
AJ Cowan, GS Laszlo, EH Estey… - Frontiers in Bioscience …, 2013 - europepmc.org
Antibodies have created high expectations for effective yet tolerated therapeutics in acute
myeloid leukemia (AML). Hitherto the most exploited target is CD33, a myeloid differentiation …
myeloid leukemia (AML). Hitherto the most exploited target is CD33, a myeloid differentiation …
[PDF][PDF] Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin
AJ Cowan, GS Laszlo, EH Estey… - Frontiers in …, 2013 - article.imrpress.com
Introduction 3. CD33, the Target Antigen 3.1. Physiological properties of CD33 3.2. CD33
Expression and internalization in AML 3.3. CD33 as a potential AML stem cell-associated …
Expression and internalization in AML 3.3. CD33 as a potential AML stem cell-associated …
Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin
AJ Cowan, GS Laszlo, EH Estey… - Frontiers in Bioscience …, 2013 - imrpress.com
Antibodies have created high expectations for effective yet tolerated therapeutics in acute
myeloid leukemia (AML). Hitherto the most exploited target is CD33, a myeloid differentiation …
myeloid leukemia (AML). Hitherto the most exploited target is CD33, a myeloid differentiation …